ENTERA BIO LTD (ENTX) Stock Fundamental Analysis
NASDAQ:ENTX - Nasdaq - IL0011429839 - Common Stock - Currency: USD
ENTX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. While ENTX has a great health rating, there are worries on its profitability. ENTX does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
ENTX had negative earnings in the past year.
In the past year ENTX has reported a negative cash flow from operations.
In the past 5 years ENTX always reported negative net income.
ENTX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of ENTX (-114.83%) is worse than 78.15% of its industry peers.
ENTX has a worse Return On Equity (-137.77%) than 62.41% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -114.83% | ||
| ROE | -137.77% | ||
| ROIC | N/A |
ROA(3y)-74%
ROA(5y)-80.42%
ROE(3y)-83.61%
ROE(5y)-98.17%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ENTX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ENTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
ENTX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ENTX has more shares outstanding
There is no outstanding debt for ENTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
ENTX has an Altman-Z score of 9.40. This indicates that ENTX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 9.40, ENTX belongs to the top of the industry, outperforming 87.59% of the companies in the same industry.
There is no outstanding debt for ENTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 9.4 |
ROIC/WACCN/A
WACC9.11%
2.3 Liquidity
A Current Ratio of 6.61 indicates that ENTX has no problem at all paying its short term obligations.
ENTX has a better Current ratio (6.61) than 66.26% of its industry peers.
A Quick Ratio of 6.61 indicates that ENTX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.61, ENTX is in the better half of the industry, outperforming 66.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.61 | ||
| Quick Ratio | 6.61 |
3. Growth
3.1 Past
ENTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 23.53%, which is quite impressive.
ENTX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)23.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
ENTX is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -34.52% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y7.87%
EPS Next 2Y-34.52%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ENTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ENTX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ENTX's earnings are expected to decrease with -34.52% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-34.52%
EPS Next 3YN/A
5. Dividend
5.1 Amount
ENTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:ENTX (3/7/2025, 8:21:57 PM)
1.89
+0.02 (+1.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners26.78%
Inst Owner Change41.1%
Ins Owners2.69%
Ins Owner Change1.17%
Market Cap69.61M
Analysts82.86
Price Target10.2 (439.68%)
Short Float %0.35%
Short Ratio0.78
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-27.45%
Min EPS beat(2)-56.86%
Max EPS beat(2)1.96%
EPS beat(4)3
Avg EPS beat(4)-5.6%
Min EPS beat(4)-56.86%
Max EPS beat(4)18.3%
EPS beat(8)6
Avg EPS beat(8)3.48%
EPS beat(12)10
Avg EPS beat(12)10.01%
EPS beat(16)13
Avg EPS beat(16)5.68%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 10.79 | ||
| P/tB | 10.79 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.26
EYN/A
EPS(NY)-0.56
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS0
BVpS0.18
TBVpS0.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -114.83% | ||
| ROE | -137.77% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-74%
ROA(5y)-80.42%
ROE(3y)-83.61%
ROE(5y)-98.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 13.73% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.61 | ||
| Quick Ratio | 6.61 | ||
| Altman-Z | 9.4 |
F-Score4
WACC9.11%
ROIC/WACCN/A
Cap/Depr(3y)51.23%
Cap/Depr(5y)50.74%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y7.87%
EPS Next 2Y-34.52%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y31.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y38.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.5%
OCF growth 3YN/A
OCF growth 5YN/A